DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1

DOSING REGIMEN FOR COMBINATION THERAPY TARGETING DLL3 AND PD-1

The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent and an anti-PD-1 antibody. Step dosing of the anti-DLL3 agent is also disclosed. La présente invention concerne une méthode de traitemen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SADRAEI, NOOSHIN HASHEMI, SMIT, MARIE-ANN DAMIETTE, WONG, HANSEN, ROYCHOUDHURY, SIDDHARTHA, MINOCHA, MUKUL, SHETTY, ADITYA
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent and an anti-PD-1 antibody. Step dosing of the anti-DLL3 agent is also disclosed. La présente invention concerne une méthode de traitement du cancer ou du cancer du type DLL3-positif ou SCLC, comprenant l'administration à un sujet dont l'état le nécessite, d'un agent anti-DLL3 et d'un anticorps anti-PD-1. L'invention divulgue, en outre, l'étape de dosage de l'agent anti-DLL3.